Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Analysts have nudged their fair value estimate for Ambev from R$15.37 to R$16.14, signaling a revised view of what the stock could be worth under current assumptions. Behind this shift sits a split research backdrop, with some firms using the new target to argue that Ambev has room to close a valuation gap, while others keep more cautious ratings despite higher targets in both reais and U.S. dollars. As you read on, you will see how these differing views shape the evolving Ambev narrative and what it could mean for your own watchlist.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
BTG Pactual recently upgraded Ambev stock to Buy with a R$20 price target. This sits above the current fair value estimate range and points to what that firm views as additional upside potential on its research assumptions.
-
Barclays raised its Ambev price target by R$0.50. This suggests the firm sees room for improved execution or valuation support compared with its prior view, even if it has not publicly paired that move with a rating change in the available data.
🐻 Bearish Takeaways
-
UBS raised its Ambev price target to US$2.90 from US$2.65 but kept a Sell rating, indicating that, in its view, the stock price already reflects or exceeds what its current growth and execution assumptions support.
-
The recent UBS downgrade earlier in the period, followed by a higher target while retaining a bearish stance, highlights continuing concern at that firm around Ambev's risk or return profile even as its valuation model adjusts.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Ambev. See which could impact your investment.
What's in the News
-
Ambev held Ordinary and Extraordinary General Shareholders' Meetings on April 30, 2026 that approved multiple amendments to its bylaws, including updated capital figures, changes to officer roles and titles, clarification on interim dividends and interest on capital, and consolidation of bylaws articles.
-
Ambev was removed from the Brazil Corporate Sustainability Index as part of an index constituent change announced on April 29, 2026.
-
Board meetings scheduled for March 30, 2026 are set to address allocation of net income for fiscal year 2025, re-ratification of fiscal year 2024 net income, compensation for management and Fiscal Council members for 2026, and a capital increase via stock option plan issuance.
-
Board meetings on May 4 and May 15, 2026 will consider the nomination of Michel Dimitrios Doukeris as chairman, 2026 compensation for governance bodies, distributions of interest on capital including a proposed gross amount of $0.449 per share, and the election of a member of the Board of Executive Officers.
How This Changes the Fair Value For Ambev
-
The fair value range has been adjusted from R$15.37 to R$16.14.
-
The revenue growth assumption is set from 4.81% to 5.38% in R$ terms.
-
The net profit margin assumption is set from 17.29% to 18.39% on R$ earnings.
-
The future P/E multiple is set from 22.36x to 21.99x.
-
The discount rate assumption is set from 18.09% to 18.33%.
Never Miss an Update: Follow The Narrative
Narratives connect Ambev's business story, its competitive position, and its risks to the assumptions that sit behind earnings forecasts and fair value estimates. They update as new research and company news come through, so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Ambev to stay up to date on:
-
How Ambev is using digital platforms like Bees Marketplace and Zé Delivery to build direct-to-consumer channels and deepen customer engagement.
-
The role of premium, super premium, balanced choice, and non-alcoholic portfolios in shifting Ambev's mix toward higher margin categories.
-
Key risks such as heavy exposure to Brazil, pressure on core beer volumes, cost inflation, and intense competition from local and new market entrants.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABEV3.bovespa .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
